• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

0.5352 -0.0048 (-0.89%)
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 437,803
Open 0.5352
Bid (Size) 0.5135 (100)
Ask (Size) 0.5200 (100)
Prev. Close 0.5400
Today's Range 0.5352 - 0.5352
52wk Range 0.2950 - 3.150
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
October 15, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
Thursday's after hours session: top gainers and losers ↗
October 15, 2026
Via Chartmill

Performance

52-Week Range 83.0% below 52-week high
0.5352
0.2952W Low 3.1552W High
1 Week 37.0% below 1-week high
0.291W Low 0.851W High

Estrella Immunopharma, Inc. - Common Stock (ESLA) traded between $0.29 and $3.15 over the past 52 weeks and last traded at $0.54, 83.0% below its 52-week high. Over the past week it ranged between $0.29 and $0.85.

Past 12 Months
+30.5%
-12.4%
-27.9%
-67.8%
-61.5%
-68.3%
1W +$0.13
1M -$0.08
3M -$0.21
6M -$1.12
YTD -$0.85
1Y -$1.15

ESLA was -68.3% over the past year, -67.8% over six months, -61.5% year to date, +30.5% in the last week.

12 Months vs Market
ESLA
-68.3%
DIA
+12.6%
SPY
+16.0%
QQQ
+20.9%
IWM
+9.9%

Over the past 12 months ESLA returned -68.3% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +20.9% and IWM (Russell 2000) +9.9%.

Volume & Liquidity 0.33× 3-mo avg
Today 437,803 3-mo avg 1.3M
1W
16.8M
1M
3.7M
3M
1.3M
6M
698.6K
YTD
517.4K
1Y
468.3K

ESLA most recently traded 437,803 shares against a 3-month average daily volume of 1.3M.

More News

Read More
Which stocks are moving on Thursday? ↗
October 15, 2026
Via Chartmill
News headline image
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
October 14, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
On Monday, there are stocks with unusual volume. Let's take a look. ↗
October 12, 2026
Via Chartmill
These stocks are gapping in today's session ↗
October 12, 2026
Via Chartmill
These stocks are moving in today's pre-market session ↗
October 12, 2026
Via Chartmill
News headline image
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
August 11, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
August 05, 2026
Via Benzinga
News headline image
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
August 03, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
July 29, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
July 24, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
May 05, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
Which stocks are moving on Monday? ↗
April 06, 2026
Via Chartmill
News headline image
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
March 23, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
Monday's pre-market session: top gainers and losers ↗
February 09, 2026
Via Chartmill
News headline image
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 09, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
February 06, 2026
Via Chartmill
Here are the top movers in Thursday's session. ↗
February 05, 2026
Via Chartmill
Thursday's session: top gainers and losers ↗
February 05, 2026
Via Chartmill
News headline image
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 03, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering
January 07, 2026
Via Investor Brand Network
News headline image
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
January 06, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
January 05, 2026
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
December 04, 2025
From Estrella Immunopharma, Inc.
Via Business Wire

Frequently Asked Questions

Is Estrella Immunopharma, Inc. - Common Stock publicly traded?
Yes, Estrella Immunopharma, Inc. - Common Stock is publicly traded.
What exchange does Estrella Immunopharma, Inc. - Common Stock trade on?
Estrella Immunopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Estrella Immunopharma, Inc. - Common Stock?
The ticker symbol for Estrella Immunopharma, Inc. - Common Stock is ESLA on the Nasdaq Stock Market
What is the current price of Estrella Immunopharma, Inc. - Common Stock?
The current price of Estrella Immunopharma, Inc. - Common Stock is 0.5352
When was Estrella Immunopharma, Inc. - Common Stock last traded?
The last trade of Estrella Immunopharma, Inc. - Common Stock was at 10/15/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap